Phathom Pharmaceuticals, Inc. EBIT

EBIT of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including EBIT growth rates and interactive chart. Earnings before interest and taxes is an indicator of a company's profitability. One can calculate it as revenue minus all expenses, excluding tax and interest. EBIT is also referred to as operating earnings, operating profit, and profit before interest and taxes. It is the amount of profit that a company earns before interest on debt and taxes are paid.

Highlights and Quick Summary

  • EBIT for the quarter ending September 29, 2021 was $-33.1 Million (a -6.18% decrease compared to previous quarter)
  • Year-over-year quarterly EBIT decreased by -36.81%
  • Annual EBIT for 2020 was $-251 Million (a 360.01% increase from previous year)
  • Annual EBIT for 2019 was $-54.6 Million (a 2130.04% increase from previous year)
  • Twelve month EBIT ending September 29, 2021 was $-154 Million (a 0.2% increase compared to previous quarter)
  • Twelve month trailing EBIT increased by 22.93% year-over-year
Trailing EBIT for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$-154 Million $-154 Million $-139 Million $-126 Million
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EBIT of Phathom Pharmaceuticals, Inc.

Most recent EBITof PHAT including historical data for past 10 years.

Interactive Chart of EBIT of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. EBIT for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $-33.14 $-35.32 $-33.58
2020 $-52.44 $-32.83 $-20.02 $-20.38 $-251.33
2019 $-15.69 $-6.28 $-83.01 $-1.23 $-54.64
2018 $-0.27 $-2.45

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.